Race/Ethnicity | ||||||
---|---|---|---|---|---|---|
White | Black | Hispanic | API | Total | ||
N (%) | 120,435 (67.2%) | 10,637 (5.9%) | 28,380 (15.8%) | 19,691 (11.1%) | 179,143 | |
Year at diagnosis | ||||||
n | 79,226 | 6,662 | 17,054 | 11,641 | 114,583 | |
2000-2006 | % within race/ethnicity | 65.8% | 62.6% | 60.1% | 59.1% | 64.0% |
n | 41,209 | 3,975 | 11,326 | 8,050 | 64,560 | |
2007-2010 | % within race/ethnicity | 34.2% | 37.4% | 39.9% | 40.9% | 36.0% |
Socioeconomic status | ||||||
n | 25,016 | 5,454 | 14,848 | 4,550 | 49,868 | |
Lowest/Least Affluent | % within race/ethnicity | 20.8% | 51.3% | 52.3% | 23.1% | 27.8% |
n | 25,283 | 2,349 | 5,756 | 3,740 | 37,128 | |
Intermediate | % within race/ethnicity | 21.0% | 22.1% | 20.3% | 19.0% | 20.7% |
n | 70,136 | 2,834 | 7,776 | 11,401 | 92,147 | |
Highest/Most Affluent | % within race/ethnicity | 58.2% | 26.6% | 27.4% | 57.9% | 51.4% |
Age at diagnosis (years) | ||||||
n | 1,600 | 299 | 1,215 | 574 | 3,688 | |
<35 | % within race/ethnicity | 1.3% | 2.8% | 4.3% | 2.9% | 2.1% |
n | 81,900 | 8,055 | 22,331 | 15,784 | 128,070 | |
35-69 | % within race/ethnicity | 68.0% | 75.7% | 78.7% | 80.2% | 71.5% |
n | 23,132 | 1,518 | 3,466 | 2,394 | 30,510 | |
70-79 | % within race/ethnicity | 19.2% | 14.3% | 12.2% | 12.2% | 17.0% |
n | 12,223 | 672 | 1,190 | 851 | 14,936 | |
80-89 | % within race/ethnicity | 10.1% | 6.3% | 4.2% | 4.3% | 8.3% |
n | 1,580 | 93 | 178 | 88 | 1,939 | |
90+ | % within race/ethnicity | 1.3% | 0.9% | 0.6% | 0.4% | 1.1% |
AJCC stage | n | 62,693 | 4,195 | 11,321 | 9,326 | 87,535 |
Stage 1 | % within race/ethnicity | 52.1% | 39.4% | 39.9% | 47.4% | 48.9% |
n | 45,791 | 4,751 | 12,608 | 8,258 | 71,408 | |
Stage 2 | % within race/ethnicity | 38.0% | 44.7% | 44.4% | 41.9% | 39.9% |
n | 11,951 | 1,691 | 4,451 | 2,107 | 20,200 | |
Stage 3 | % within race/ethnicity | 9.9% | 15.9% | 15.7% | 10.7% | 11.3% |
ER/PR/HER2 subtype | ||||||
n | 52,797 | 3,240 | 10,526 | 7,859 | 74,422 | |
ER+/PR+/HER2- | % within race/ethnicity | 60.3% | 42.9% | 51.0% | 54.9% | 57.2% |
n | 7,689 | 709 | 2,181 | 1,665 | 12,244 | |
ER+/PR+/HER2+ | % within race/ethnicity | 8.8% | 9.4% | 10.6% | 11.6% | 9.4% |
n | 8,791 | 735 | 1,816 | 1,172 | 12,514 | |
ER+/PR-/HER2- | % within race/ethnicity | 10.0% | 9.7% | 8.8% | 8.2% | 9.6% |
n | 2,675 | 252 | 678 | 513 | 4,118 | |
ER+/PR-/HER2+ | % within race/ethnicity | 3.1% | 3.3% | 3.3% | 3.6% | 3.2% |
n | 640 | 77 | 194 | 113 | 1,024 | |
ER-/PR+/HER2- | % within race/ethnicity | 0.7% | 1.0% | 0.9% | 0.8% | 0.8% |
n | 281 | 45 | 126 | 61 | 513 | |
ER-/PR+/HER2+ | % within race/ethnicity | 0.3% | 0.6% | 0.6% | 0.4% | 0.4% |
n | 9,924 | 1,929 | 3,371 | 1,601 | 16,825 | |
ER-/PR-/HER2- | % within race/ethnicity | 11.3% | 25.5% | 16.3% | 11.2% | 12.9% |
n | 4,789 | 572 | 1,748 | 1,329 | 8,438 | |
ER-/PR-/HER2+ | % within race/ethnicity | 5.5% | 7.6% | 8.5% | 9.3% | 6.5% |
Tumor grade | n | 29,749 | 1,516 | 4,613 | 3,454 | 39,332 |
Grade I | % within race/ethnicity | 26.2% | 15.1% | 17.3% | 18.6% | 23.3% |
n | 49,124 | 3,570 | 10,610 | 7,972 | 71,276 | |
Grade II | % within race/ethnicity | 43.3% | 35.5% | 39.8% | 43.0% | 42.3% |
n | 32,747 | 4,691 | 10,823 | 6,785 | 55,046 | |
Grade III | % within race/ethnicity | 28.9% | 46.7% | 40.6% | 36.6% | 32.6% |
n | 1,802 | 276 | 620 | 345 | 3,043 | |
Grade IV | % within race/ethnicity | 1.6% | 2.7% | 2.3% | 1.9% | 1.8% |